Newsletter of MEDICA | View in browser | Deutsch | Print
Header of MEDICA Newsletter

Illuminated pajama for the mobile therapy of jaundice

Dear Sir or Madam,

Many young families are confronted with the issue of jaundice in newborns. Until now, there have been special incubators for treating the disease, in which babies were irradiated with blue light. A illuminated pajama developed by Empa researchers is now to enable treatment at home. Thus parents could avoid a separation from their children in this critical phase. Read more in our current interview.

I wish you a snowy week,

Julia Unverzagt
Editorial team MEDICA-tradefair.com
image: 12 - 15 November 2018, MEDICA - World Forum for Medicine in Düsseldorf

Table of Contents

Interview: Illuminated pajama
Topic of the Month: Innovation Office of the BfArM
Newsletter Service
RSS Service
Newsletter Archive

Illuminated pajamas treat jaundice in mommy's arms

Interview

Image: Woman holding a doll in a glowing pyjamas; Copyright: Empa
Sixty percent of newborns are affected by jaundice during their first days of life. In most cases, the condition is harmless. The ailment is more pronounced in premature babies, whose treatment involves irradiation with blue light in a special incubator – naked and alone. The materials scientists at Empa now want to customize this method to the needs of babies and thus significantly improve the treatment.
Read the interview here:
Illuminated pajamas treat jaundice in mommy's arms
All interviews at MEDICA-tradefair.com
To top

Research & Technology

Higher blood sugar in early pregnancy raises baby's heart-defect risk

Higher blood sugar early in pregnancy raises the baby's risk of a congenital heart defect, even among mothers who do not have diabetes, according to a study led by researchers at the Stanford University School of Medicine.
read more
To top

Research & Technology

Noise sens­it­iv­ity vis­ible in brain struc­tures

A new study suggests that noise sensitivity can be seen in the grey matter volume of brain structures linked to emotional and interoceptive processing.
read more
To top

Research & Technology

Groundbreaking gene therapy trial set to cure haemophilia

A "cure" for haemophilia is one step closer, following results of a groundbreaking gene therapy trial led by the NHS in London.
read more
To top

Research & Technology

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.
read more
To top

Research & Technology

Nanoparticles as a Solution against Antibiotic Resistance?

Scientists of the Friedrich Schiller University Jena, Germany succeeded in developing an efficient method to treat Mucoviscidosis. Crucial are nanoparticles that transport the antibiotics more efficiently to their destination.
read more
To top

Research & Technology

Research points to second chance for rejected antibiotic candidate

An antibiotic candidate compound shelved in the 1970s in favour of more worthwhile drugs could be worth a second look, new research has found.
read more
To top

Innovation Office: accreditation and certification consulting services for startups

Topic of the Month

Image: View from above onto a table showing the hands of several people and papers; Copyright: panthermedia.net/pressmaster
The road to a marketable medical device is long and winding. Devices must meet specific regulatory requirements for medical applications. It is especially challenging for startup businesses to stay on top of these criteria. That's why the German Federal Institute for Drugs and Medical Devices has started to offer the Innovation Office since the beginning of this year – an information hub for startup companies.
Read more in our Topic of the Month:
Innovation Office: accreditation and certification consulting services for startups
When is a medical device considered to be a medical device? – Certification, norms, and standards

Newsletter Service

You like our newsletter? Then please recommend us: Forward this newsletter or the link www.MEDICA.de/news_login_2 to your friends and colleagues.

If you have difficulties with your order, please write an e-mail to redaktion@medica.de.
To top

beta-web GmbH - Partner of Messe Düsseldorf

Advertising Opportunities

As an official partner of Messe Düsseldorf, beta-web markets exclusive forms of advertisements to exhibitors of the MEDICA.

You want to be part of the newsletter and reach over 30.000 interested readers with your advertising message? Then contact us at medica@beta-web.de or call us: 0049 – 228 9193735.

For more information on our available forms of advertisements, please see our Media Kit.
Website of beta-web GmbH
To top
Legal disclaimer

Messe Düsseldorf GmbH
Messeplatz, Stockumer Kirchstr. 61
40474 Düsseldorf, Germany

Phone: +49 (0)211 / 4560-01
Fax: +49 (0)211 / 4560-668
www.messe-duesseldorf.de
info@messe-duesseldorf.de

County Court Düsseldorf HRB 63

Board of Managing Directors: Werner M. Dornscheidt (Chairman), Hans Werner Reinhard, Joachim Schäfer, Bernhard Stempfle

Chairman of Supervisory Board: Mayor Thomas Geisel

Facebook Twitter LinkedIn YouTube

Should you no longer wish to receive our newsletter, please click here.